Skip to content

News

Connecting Survivors to the Science | Meet a Research Advocate

Connecting Survivors to the Science | Meet a Research Advocate

To speak with Kimberly Richardson is to feel an instant camaraderie with someone who exhibits both calm and conviction, thoughtfulness and frank talk. She has learned a lot in the past 20 years – running triathlons, running a nonprofit in Chicago focused on small business development, teaching urban sociology as an adjunct professor – and … Continued

A Statement from OCRA

A Statement from OCRA

If there’s one thing that working toward an end to ovarian cancer has taught us, it’s that life is precious. We value the life of every person in our ovarian cancer community, and celebrate its diversity and strength. But today we stand in solidarity with our ovarian cancer community–and communities all over this country–in saying … Continued

Inspired Advice: What Do You Need Most from a Life Partner?

Inspired Advice: What Do You Need Most from a Life Partner?

Those who have faced an ovarian or gynecologic cancer diagnosis have so much to offer to others going through a similar experience – be it support, tips or friendship. Inspired Advice is a blog series that tackles specific topics – from managing treatment-related nausea to intimacy post-diagnosis – and shares advice and reflections from our OCRA Inspire … Continued

Speaking Out for Those Who Can’t | Meet an Advocate Leader

Speaking Out for Those Who Can’t | Meet an Advocate Leader

In 2005, Denise Lobodinski’s sister Renee was diagnosed with ovarian cancer at the age of 47. That same year, their father was diagnosed with prostate cancer. But her father’s doctor told Denise’s mother, “Don’t worry about your husband. Worry about your daughter.” In fifteen years, Denise feels like very little has changed in terms of … Continued

Survey: Navigating Treatment in the Time of Covid-19

Survey: Navigating Treatment in the Time of Covid-19

Covid-19 has disrupted nearly every aspect of life as we know it, and navigating a diagnosis and treatment for ovarian cancer – already a game changer – has been impacted as well. We want to better understand from our community exactly how this pandemic is affecting access to, and decisions around, treatment and clinical trials … Continued

When a Virus is a Good Thing | Meet a Scientist

When a Virus is a Good Thing | Meet a Scientist

Scared. Overwhelmed. Exhausted. Befuddled.  These are common words one might use to describe how we feel during this unprecedented time in history. But Dmitriy Zamarin, MD, PhD, adds “fascinated” to the list as he ponders the psychological and sociological implications of the Covid-19 pandemic. “This small amount of genetic material that has spread through the … Continued

Reflections from the Frontline | OCRA Scientists on Covid-19

Reflections from the Frontline | OCRA Scientists on Covid-19

We reached out to our grantees and Scientific Advisory Committee, many of whom are on the frontlines – working in hospitals, meeting with patients, seeing firsthand the impact of Covid-19. We wanted to hear their words and reflections. “What do you wish everyone understood right now?” we asked them. “And what gives you hope?” Here … Continued

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means … Continued

Update on OCRA’s 2020 Ovarian Cancer National Conference

Update on OCRA’s 2020 Ovarian Cancer National Conference

(May 4, 2020) Many of you in our strong community have inquired about plans for our 2020 National Conference, originally scheduled for July 10-12 in Washington DC.  The past two months have been wait and see due to COVID-19, and we can’t say for sure what regulations will look like come July, but we know this: … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.